The aim of this study was to explore patients’ knowledge and perspectives in Istanbul, Turkey about the pharmaceutical regulatory review and reimbursement processes with respect to access to new medicines. Participants considered faster access to medicines, improved health and pharmaceutical care as well as lower prices to be priorities for improvement. The study also highlighted a need to involve patient associations in decision making regarding new medicines and ensure considerable public representation in the process.
